Live Biotherapeutics Drug Discovery Service for Hyperuricemia
Creative Biolabs, headquartered in New York, USA, is a world-renowned provider of biotechnology contract research services. We focus on live biotherapeutics and next-generation probiotics research. We support academic laboratories and small biotech start-ups from around the world to global biopharmaceutical companies. When you wish to commission a project research partner, you can benefit from our expertise.
Overview of Hyperuricemia
Hyperuricemia is well-known as a cause of gout. In recent years, many epidemiological studies have also found a correlation between hyperuricemia and the development of hypertension, obesity, renal disease, cardiovascular disease, and diabetes. Studies in animal models suggested that cardiovascular and kidney diseases could benefit from lowering serum uric acid. Research has shown that probiotics have the potential to improve animal hyperuricemia.
Changes of Gut Microbiota Composition and Hyperuricemia
Changes in the abundance and composition of gut microbiota lead to an increase in serum uric acid levels through impaired uric acid degradation and increased uric acid production.
-
Metabolism of Gut Microbiota in Hyperuricemia
Dysfunction in gut microbiota metabolism may affect serum uric acid levels by affecting host metabolites.
Gut Microbiota as a Potential Therapeutic Target in Hyperuricemia
Hyperuricemia has been studied mainly through the analysis of gut microbiota. Progress has been made in the use of probiotics in the treatment of hyperuricemia and gout. The Clostridiaceae family has been reported to have the ability to degrade uric acid. Lactobacillus rhamnosus and Lactobacillus reuteri can promote the production of SCFAs and reduce serum and uric acid concentrations in hyperuricemic mice in a purine-independent manner. Lactobacillus fermentum GR-3 can reduce the amount of uric acid absorbed by the intestinal epithelium into the bloodstream, reduce inflammation in the body, protect intestinal and renal function, and promote uric acid excretion. These results suggest that the gut microbiota may be involved in the pathogenesis of hyperuricemia and may serve as a new target for alleviating and treating hyperuricemia and related diseases.
The Mechanism of the Gut Microbiota Contribution to Hyperuricemia
-
Gut microbiota promotes purines and uric acid catabolism.
-
Metabolites of the gut microbiota increase uric acid excretion.
-
Transporters in the gut mediate uric acid excretion.
-
Gut microbiota and chronic inflammatory mechanisms of hyperuricemia.
Next-generation Probiotic Strains at Creative Biolabs
Creative Biolabs can offer a range of next-generation probiotics for live biotherapeutics research, including but not limited to the following, click on Probiotic Strains to check out more strains you might be interested in.
Our Services for the Following Types/Similar Hyperuricemia Research
|
Research Article
|
Available Services
|
|
Probiotic effects of Lacticaseibacillus rhamnosus 1155 and Limosilactobacillus fermentum 2644 on hyperuricemic rats.2
|
|
|
Supplementation of Lactobacillus plantarum (TCI227) prevented potassium-oxonate-induced hyperuricemia in Rats.3
|
|
|
Lactobacillus paracasei X11 ameliorates hyperuricemia and modulates gut microbiota in mice.4
|
|
With over 10 years of industry experience, Creative Biolabs is always based on maintaining quality and strong integrity, providing reliable quality products and services is our passion. This is how we help the life science community thrive and help more researchers get the best tools to move forward. If you are interested in our services, please do not hesitate to contact us.
References
-
Li, Yanjun, et al. "Probiotic effects of Lacticaseibacillus rhamnosus1155 and Limosilactobacillus fermentum 2644 on hyperuricemic rats." Frontiers in Nutrition 9 (2022): 993951.
-
Chien, Chih-Yu, et al. "Supplementation of Lactobacillus plantarum (TCI227) prevented potassium-oxonate-induced hyperuricemia in rats." Nutrients 14.22 (2022): 4832.
-
Cao, Jiayuan, et al. "Lactobacillus paracasei X11 ameliorates hyperuricemia and modulates gut microbiota in mice." Frontiers in Immunology 13 (2022): 940228.
-
Distributed Under Open Access license CC BY 4.0, without modification.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
